Experiments using breast cancer patient-derived xenografts revealed that paclitaxel treatment activates type I IFN and TNFα and that a cGAS-STING-dependent apoptotic effect is required for the paclitaxel response in vivo [39]. This evidence concerns the gene CGAS and breast cancer.